|Regulus Therapeutics Inc.|
3545 John Hopkins Court
United States - Map
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. It uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. The companys clinical stage products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection; and RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease. It has strategic collaborations with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases. The company also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 preclinical fibrosis program for the treatment of Alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
|Regulus Therapeutics Inc.’s ISS Governance QuickScore as of Apr 1, 2015 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 5; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Kleanthis G. Xanthopoulos Ph.D.,
Chief Exec. Officer, Pres, Principal Financial & Accounting Officer and Director
|Dr. Neil W. Gibson Ph.D.,
Chief Scientific Officer
| Amy Conrad ,
Director of Investor Relations & Corp. Communications
|Mr. David L. Szekeres ,
Chief Bus. Officer, Gen. Counsel and Sec.
|Dr. Zachary A. Zimmerman Ph.D.,
Director of Bus. Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|